Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients

Drugs

Volumn 61, Issue 8, 2001, Pages 1153-1183

  McGavin, J K ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; THYMOCYTE ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; HEART TRANSPLANTATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORGAN TRANSPLANTATION; PROPHYLAXIS; RECURRENT INFECTION; REVIEW; THROMBOCYTOPENIA;

EID: 0034933929     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161080-00016     Document Type: Review

References (105)

1. Ganciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections
2. Ganciclovir: An update of its therapeutic use in cytomegalovirus infection
3. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients
4. Human herpesviruses in transplant patients
5. Summary of the II International Symposium on Cytomegalovirus
6. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients
7. Ganciclovir
8. Antiviral activity and mechanims of action of ganciclovir
9. Resistance of human cytomegalovirus to antiviral drugs
10. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation
11. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
12. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis
13. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation
14. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function
15. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
16. Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics
17. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis
18. Oral absorption of ganciclovir in children following liver transplantation
19. Cytomegalovirus in transplantation: New developments
20. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: A retrospective study
21. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989
22. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients
23. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
24. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation
25. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia
26. Randomized, multicenter, open-label trial of foscarnet (FOS) versus ganciclovir (GCV) for preemptive therapy of cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT)
27. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): A randomised study
28. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation
29. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged preemptive ganciclovir therapy
30. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients
31. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
32. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients
33. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial
34. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy
35. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection
36. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients
37. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients
38. A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant 'CMV at risk' recipients
39. Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant 'CMV at risk' recipients: A controlled, comparative study of two regimens (750 mg bid and 500 mg bid)
40. Comparison of ganciclovir- and immune globulin-containing regimens in preventing cytomegalovirus infection in patients with renal transplants
41. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy
42. Superior cytomegalovirus prophylaxis with oral ganciclovir compared to oral acyclovir in pediatric renal transplant recipients
43. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy
44. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients; effect of oral ganciclovir
45. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients
46. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients
47. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation
48. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin
49. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients
50. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation
51. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation
52. Efficacy of IV ganciclovir followed by oral therapy for the prevention of CMV infection in lung transplant recipients
53. Effects or oral ganciclovir on the prevention of cytomegalovirus infection in lung transplant recipients
54. Prophylaxis of CMV disease in lung transplantation: Intravenous vs oral ganciclovir
55. A novel regimen of delayed ganciclovir reduced CMV disease in lung transplant patients
56. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients
57. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients
58. Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database
59. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children
60. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
61. A double blinded placebo controlled randomized trial evaluating preemptive therapy with oral ganciclovir based on the detection of cytomegalovirus DNA post liver transplantation
62. Pre-emptive ganciclovir therapy based on PCR compared with prophylaxis for prevention of CMV disease in high risk liver transplant recipients
63. Oral ganciclovir monotherapy in the prevention of cytomegalovirus disease in liver transplant recipients
64. Intravenous versus oral ganciclovir in the prevention of cytomegalovirus in liver transplant recipients
65. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus IV ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, controlled trial
66. Preemptive therapy in CMV-antigen positive patients after liver transplantation - A prospective trial
67. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation
68. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
69. Is cytomegalovirus prophylaxis with ganciclovir in non-induction heart transplant patients effective?
70. Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients
71. Ganciclovir prophylaxis alone is equally effective to a combined regimen of acyclovir with Cytogam® (CMVIg) in preventing cytomegaloviral infection in heart transplant recipients
72. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study
73. Preemptive antiviral therapy in cytomegalovirus negative recipients of hearts from CMV positive donors is superior to prophylaxis
74. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
75. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
76. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome
77. Current management strategies for the treatment and prevention of cytomegalovirus infection in solid organ transplant recipients
78. Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir
79. Psychotic symptoms and confusion associated with intravenous ganciclovir in a heart transplant recipient
80. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient
81. The cost impact of cytomegalovirus disease in renal transplant patients
82. Which renal transplant patients should receive cytomegalovirus immune globulin?
83. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation: Comparing valaciclovir prophylaxis with current practice
84. Clinical and economic impact of oral ganciclovir prophylaxis of CMV-disease in renal transplantation
85. A 3-year follow-up of pre-emptive vs deferred treatment of cytomegalovirus disease in renal transplantation
86. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients
87. Cost-effectiveness analysis of prophylactic therapies for CMV disease after liver transplantation
88. Cost-effectiveness of ganciclovir in prevention of cytomegalovirus disease after liver transplantation: A Bayesian approach
89. Clinical practice guidelines: Prevention of cytomegalovirus disease after renal transplantation
90. Cytomegalovirus prophylaxis in solid organ transplant recipients: The issues
91. Valganciclovir
92. Management of cytomegalovirus infection after liver transplantation
93. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant
94. Prophylaxis against herpesvirus infections in transplant recipients
95. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy
96. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: Results of a placebo-controlled, double-blind trial
97. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
98. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
99. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation
100. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation
101. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
102. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after prophylaxis